Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05296473 · ClinicalTrials.gov registry record · NA

Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

A NA study of ADHD, sponsored by Lumos Labs.

Completed
Registry status
NA
Development phase
560
Enrollment target
13
Study locations

NCT05296473 is a NA study of ADHD that has completed, run by Lumos Labs. The registered enrollment target is 560 participants, above the 183-participant average among 75 other ADHD trials with a reported enrollment target (206% higher). The trial reports 13 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05296473, a NA study of ADHD, has completed, sponsored by Lumos Labs.

COMPLETED
Registry status
NA
Development phase
560 participants
Enrollment target
13
Study locations

Study Summary

The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Conditions Studied

Interventions

  • DEVICE ADHD Therapy
  • DEVICE Control Therapy

Study Locations (13)

California

  • CNS Network - Garden Grove
  • University of California Davis MIND Institute - Sacramento
  • University of California San Francisco - San Francisco

North Carolina

  • Duke University - Durham
  • Mindpath Care Centers - Raleigh

Arizona

  • Melmed Center - Scottsdale

Florida

  • Accel Research Sites - Maitland Clinical Research Unit - Maitland

Missouri

  • Midwest Research Group - Saint Charles

Nebraska

  • Alivation Research, LLC - Lincoln

Nevada

  • Center of Psychiatry and Behavioral Medicine - Las Vegas

New Jersey

  • Center for Emotional Fitness - Cherry Hill

Trial Details

FieldValue
Enrollment Target 560 participants
Start Date 2022-05-05
Est. Completion 2024-03-12
Phase NA

Sponsor

Lumos Labs

9 total trials

What the Registry Record Tells You About NCT05296473

The ClinicalTrials.gov registry entry for NCT05296473 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 183-participant average among 75 other ADHD trials with a reported enrollment target (206% higher). The listed sponsor is Lumos Labs, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which ADHD Therapy is the first listed.

NCT05296473 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, North Carolina, Arizona.

Frequently Asked Questions

What is clinical trial NCT05296473 about?

NCT05296473 is a clinical study titled "Guided ADHD Therapy for Managing the Extent and Severity of Symptoms". The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

What is the current status of trial NCT05296473?

This trial is currently completed. It is a NA study. The enrollment target is 560 participants. The study started on 2022-05-05. Estimated completion is 2024-03-12.

What conditions does trial NCT05296473 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT05296473?

The interventions under investigation include: ADHD Therapy (DEVICE), Control Therapy (DEVICE).

Who is sponsoring clinical trial NCT05296473?

This trial is sponsored by Lumos Labs, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05296473 being conducted?

This trial has 13 study locations across Arizona, California, Florida, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.